Company: EMD Serono
Job title: Director
Dr. Brian Rabinovich earned his PhD in Immunology at the University of Toronto in 2002 and postdoctoral training in cellular and protein engineering at Immunex Corp. in Seattle, WA. His graduate and postdoctoral studies focused on the interface between innate and adaptive immunity with a bias on the impact of NK cells on T cell biology. During his graduate work, Dr. Rabinovich also worked as a Scientist at Vasogen Inc. studying the impact of apoptotic cells on immune tolerance in the setting of Rheumatoid Arthritis. Dr. Rabinovich identified NKG2D as the receptor responsible for the recognition of activated T cells and double positive thymocytes and proposed the hypotheses for the regulation of T cell development and immune responses via interaction of NKG2D with its ligands. Dr. Rabinovich later worked at MD Anderson Cancer Center on the genetic engineering of CAR-T and Tumor Infiltrating Lymphocytes while developing T cell engagers through external collaborations. Dr. Rabinovich was involved in the development of membrane bound IL-15 and transposon based CAR-T, the IP from which was licensed by Intrexon and Zyopharm in 2014. In 2016, Brian Rabinovich joined EMD Serono where he is a Director in the department of Immuno-Oncology, exploring the role of T cells and NK cells in the tumor microenvironment. His major focus is the development of biologics that circumvent immuno-inhibitory molecules and cells in the tumor microenvironment and redirect the specificity of T cells and NK cells towards tumors.
Comparing the Biology of Conditional Agonists Targeting CD3, the g9d2 TCR and NK Activation Receptors 2:00 pm
The biology of activating ab T cells, g9d2 T cells and NK cells Advantages and disadvantages to conditional agonists targeting each cell type Challenges and opportunities associated with targeting activation receptors expressed on multiple effector cell typesRead more
day: Day Two